Syncom Formul.

{
  "main_header": {
    "sid": 831770,
    "name": "Syncom Formul.",
    "stock_name": "Syncom Formul.",
    "full_name": "Syncom Formulations (India) Ltd",
    "name_url": "stocks-analysis/syncom-formul",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "14.29",
    "chg": 0.41,
    "chgp": "2.95%",
    "dir": 1,
    "prev_price": "13.88",
    "mcapval": "1,342.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524470,
    "symbol": "SYNCOMF",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE312C01025",
    "curr_date": "Jun 12, 03:30 PM",
    "curr_time": "10:42 AM",
    "last_traded_at": "Jun 12, 03:30 PM IST",
    "bse_nse_vol": "16.1 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 12, 2026",
    "traded_date_str": "2026 06 12",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/syncom-formul-831770-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-4046387",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/SyncomFormulati_mojoScore_4046387.png",
        "date": "2026-06-11 10:10:57",
        "description": "Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-4024226",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SyncomFormulati_mojoScore_4024226.png",
        "date": "2026-05-31 10:10:42",
        "description": "Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 May 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Syncom Formulations Valuation Shifts Signal Growing Price Pressure Amid Sector Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syncom-formulations-valuation-shifts-signal-growing-price-pressure-amid-sector-dynamics-4012450",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SyncomFormulati_valuationdot_4012450.png",
        "date": "2026-05-26 08:01:25",
        "description": "Syncom Formulations (India) Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite a strong recent price rally, the company’s valuation now demands closer scrutiny against its historical averages and peer group benchmarks within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Are Syncom Formulations (India) Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-syncom-formulations-india-ltd-latest-results-good-or-bad-4008951",
        "imagepath": "",
        "date": "2026-05-23 19:22:53",
        "description": "Syncom Formulations (India) Ltd's latest financial results for Q4 FY26 present a complex picture of the company's performance. The company reported a net profit of ₹25.17 crores, reflecting a significant year-on-year increase of 42.28%, and a quarter-on-quarter growth of 33.10%. This profit growth is notable, yet it is essential to recognize that it is heavily influenced by non-operating income, which constituted a substantial portion of the profit before tax.\n\nIn terms of revenue, Syncom recorded ₹135.41 crores, which represents a year-on-year decline of 9.05%, continuing a trend of revenue volatility. However, on a quarter-on-quarter basis, revenue showed a recovery with a growth of 17.60%, following a previous decline in the prior quarter. This indicates some short-term operational recovery, but the longer-term revenue trajectory remains concerning, particularly given the company's five-year sales declin..."
      },
      {
        "title": "Syncom Formulations Q4 FY26: Strong Profit Growth Masks Structural Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/syncom-formulations-q4-fy26-strong-profit-growth-masks-structural-concerns-4008386",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SyncomFormulati_quaterlyResult_4008386.png",
        "date": "2026-05-23 11:47:43",
        "description": "Syncom Formulations (India) Ltd. reported a robust 42.28% year-on-year surge in net profit to ₹25.17 crores for Q4 FY26, marking its strongest quarterly performance in recent history. However, the headline numbers conceal troubling undercurrents: a 9.05% revenue decline compared to the previous year, heavy reliance on non-operating income, and a five-year sales contraction that raises serious questions about the company's core business vitality. Trading at ₹14.33 with a market capitalisation of ₹1,346 crores, the micro-cap pharmaceutical manufacturer faces mounting investor scepticism as the stock has surrendered 27.44% over the past year."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-4000699",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SyncomFormulati_mojoScore_4000699.png",
        "date": "2026-05-20 10:10:56",
        "description": "Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO, with this rating last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook."
      },
      {
        "title": "When is the next results date for Syncom Formulations (India) Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-syncom-formulations-india-ltd-3991869",
        "imagepath": "",
        "date": "2026-05-14 23:16:59",
        "description": "The next results date for Syncom Formulations (India) Ltd is scheduled for 22 May 2026...."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-3982736",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/SyncomFormulati_mojoScore_3982736.png",
        "date": "2026-05-09 10:10:36",
        "description": "Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-3966328",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SyncomFormulati_mojoScore_3966328.png",
        "date": "2026-04-28 10:10:55",
        "description": "Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company's performance and outlook."
      }
    ],
    "total": 276,
    "sid": "831770",
    "stock_news_url": "https://www.marketsmojo.com/news/syncom-formulations-india-831770"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "23-May-2026",
      "details": "Submission of Press Clipping related to extract of Audited Financial Results for the year ended 31.03.2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Regulation 33(3)(D) Of SEBI (LODR) Regulations 2015-Submission Of Standalone & Consolidated Audited Financial Results Along With Audit Report Statement Of Assets And Liabilities And Cash Flow For The Year Ended On 31St March 2026",
      "datetime": "22-May-2026",
      "details": "Pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations 2015 we are pleased to submit the Standalone & Consolidated Audited Financial Results along with Auditors Report thereon by Statutory Auditors Statement of Assets and Liabilities and Cash Flow for the quarter/year ended on 31st March 2026 in PDF Format which were approved by the Audit Committee and Board of Directors at their meeting held on Friday 22nd May 2026.",
      "source": "BSE"
    },
    {
      "caption": "Regulation 33(3)(D) Of SEBI (LODR) Regulations 2015-Submission Of Standalone & Consolidated Audited Financial Results Along With Audit Report Statement Of Assets And Liabilities And Cash Flow For The Year Ended On 31St March 2026.",
      "datetime": "22-May-2026",
      "details": "Pursuant to regulation 33(3)(d) of SEBI LODR Regulations 2015 we are pleased to submit the financials for the year ended on 31st March 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has declared <strong>3%</strong> dividend, ex-date: 09 Sep 22",
          "dt": "2022-09-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>1:10</strong> stock split, ex-date: 19 Aug 13",
          "dt": "2013-08-19",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>5:2</strong> bonus issue, ex-date: 19 Aug 13",
          "dt": "2013-08-19",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>1:2</strong> rights issue, ex-date: 13 May 09",
          "dt": "2009-05-13",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Syncom Formulations (India) Ltd is Rated Sell

2026-06-11 10:10:57

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-05-31 10:10:42

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Syncom Formulations Valuation Shifts Signal Growing Price Pressure Amid Sector Dynamics

2026-05-26 08:01:25

Syncom Formulations (India) Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite a strong recent price rally, the company’s valuation now demands closer scrutiny against its historical averages and peer group benchmarks within the Pharmaceuticals & Biotechnology sector.

Read full news article

Are Syncom Formulations (India) Ltd latest results good or bad?

2026-05-23 19:22:53

Syncom Formulations (India) Ltd's latest financial results for Q4 FY26 present a complex picture of the company's performance. The company reported a net profit of ₹25.17 crores, reflecting a significant year-on-year increase of 42.28%, and a quarter-on-quarter growth of 33.10%. This profit growth is notable, yet it is essential to recognize that it is heavily influenced by non-operating income, which constituted a substantial portion of the profit before tax. In terms of revenue, Syncom recorded ₹135.41 crores, which represents a year-on-year decline of 9.05%, continuing a trend of revenue volatility. However, on a quarter-on-quarter basis, revenue showed a recovery with a growth of 17.60%, following a previous decline in the prior quarter. This indicates some short-term operational recovery, but the longer-term revenue trajectory remains concerning, particularly given the company's five-year sales declin...

Read full news article

Syncom Formulations Q4 FY26: Strong Profit Growth Masks Structural Concerns

2026-05-23 11:47:43

Syncom Formulations (India) Ltd. reported a robust 42.28% year-on-year surge in net profit to ₹25.17 crores for Q4 FY26, marking its strongest quarterly performance in recent history. However, the headline numbers conceal troubling undercurrents: a 9.05% revenue decline compared to the previous year, heavy reliance on non-operating income, and a five-year sales contraction that raises serious questions about the company's core business vitality. Trading at ₹14.33 with a market capitalisation of ₹1,346 crores, the micro-cap pharmaceutical manufacturer faces mounting investor scepticism as the stock has surrendered 27.44% over the past year.

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-05-20 10:10:56

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO, with this rating last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Read full news article

When is the next results date for Syncom Formulations (India) Ltd?

2026-05-14 23:16:59

The next results date for Syncom Formulations (India) Ltd is scheduled for 22 May 2026....

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-05-09 10:10:36

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-04-28 10:10:55

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company's performance and outlook.

Read full news article

View All News